Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anzjph.2024.100200 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.
Eur Psychiatry
January 2025
Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium.
Background: Recent years show an exponential increased interest ("renaissance") in the use of psychedelics for the treatment of mental disorders and broader. Some of these treatments, such as psilocybin for depression, are in the process of formal regulation by regulatory bodies in the US (FDA) and Europe (EMA), and as such on the brink of real-world implementation. In the slipstream of these developments increasing commercial initiatives are taking shape.
View Article and Find Full Text PDFPsychedelic-assisted therapy - supposedly paradigm-shifting research with poor attempts at hypotheses falsifying and questionable ethics.
EXCLI J
December 2024
Department of Biochemistry, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore.
Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants: A Randomized Controlled Trial.
Int J Neuropsychopharmacol
January 2025
Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland.
Background: Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable therapeutic effects in various psychiatric conditions. This traditional Amazonian plant decoction contains N,N-dimethyltryptamine (DMT) and β-carboline alkaloids such as harmine. However, its use is often accompanied by distressing effects like nausea, vomiting, and intense hallucinations, possibly due to complex pharmacokinetic/pharmacodynamic (PK-PD) interactions and lack of dose standardization.
View Article and Find Full Text PDFA Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy.
J Psychoactive Drugs
January 2025
Psychiatry, McLean Hospital, Belmont, MA, USA.
As psilocybin awaits approval by the Food and Drug Administration (FDA), scholars debate whether psychedelic-assisted psychotherapy should be required when prescribing this medicine. Here, we report the case of a patient who underwent a psilocybin experience without psychedelic-assisted psychotherapy, resulting in inpatient psychiatric admission. This case underscores the importance of taking psilocybin in controlled clinical settings.
View Article and Find Full Text PDFKetamine-Assisted Psychotherapy for Antisocial Personality Disorder: A Case Report.
J Psychoactive Drugs
January 2025
Helfgott Research Institute, National University of Natural Medicine, Portland, OR USA.
There are currently no evidence-based treatment guidelines for antisocial personality disorder (ASPD). Instead, treatment typically focuses on comorbid conditions. There is currently no literature documenting cases or research, theoretical or otherwise of using ketamine-assisted therapy or any other psychedelic therapy in cases of ASPD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!